Oratos AI
Oratos AI
  • Home
  • About Us
    • About BrIM AI
    • Who We Are
  • Contact Us
  • More
    • Home
    • About Us
      • About BrIM AI
      • Who We Are
    • Contact Us
  • Home
  • About Us
    • About BrIM AI
    • Who We Are
  • Contact Us

What BrIM AI Reveals

We show tumor infiltration that standard MRIs cannot.

Refined Treatment Planning

Safely target infiltrating tumor while sparing healthy tissue

The BrIM AI platform has been used to guide surgical biopsies, radiation treatment, diagnose glioblastoma, and assess other diseases for adult and pediatric patients

Clinical Evidence

Multi-site trial (NCT03137888): 

Physicians at 3 institutions used BrIM AI to guide radiation treatment. Survival improved from 15 → 23 months, and tumor recurrence delayed from 5 -> 16 months; with minimal side effects



What's Next?

Support two upcoming national clinical trials

BrIM AI will be disseminated to 75+ hospitals throughout the country. The first trial will use BrIM AI to assess brain tumor recurrence, while the second trial uses BrIM AI to guide radiation treatment of recurrent glioblastoma. More trials are in concept for lower grade gliomas and other diseases.

Secure FDA Approval

With suitable predicate software guiding radiation treatment in the market, we plan to secure FDA approval over the next two years for our imaging platform.

Commercial Launch!

Copyright © 2025 Oratos AI - All Rights Reserved.

Powered by

This website uses cookies.

We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.

Accept